On May 22, 2025, Rigel Pharmaceuticals, Inc. stockholders approved an amendment to the 2018 Equity Incentive Plan, adding 700,000 shares for issuance. Other votes included the election of directors and ratification of Ernst & Young as auditors for 2023.